Brief: EQL Pharma Expects Growth Rate Of Around 40% For Full Year 2024/25

EQL Pharma AB

06/11/2024 06:13

Nov 6 (Reuters) - EQL Pharma AB  EQL.ST :
    * GROSS MARGIN WAS NEGATIVELY IMPACTED BY ONGOING LOGISTICAL
CHALLENGES RELATED TO SITUATION IN RED SEA
    * FOR FULL YEAR 2024/25, WE EXPECT A GROWTH RATE OF AROUND
40%
    * OUR GOAL IS TO ACHIEVE AN EBITDA MARGIN OF AT LEAST 25%
DURING
LAST QUARTER OF 2024/25

Source text:  ID:nWkr7FF2hB 
Further company coverage:  EQL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))